What Is 2019-nCoV acute respiratory disease

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2019-nCoV acute respiratory disease, later named COVID-19, is caused by the SARS-CoV-2 virus first identified in Wuhan, China, in December 2019. The World Health Organization declared it a global pandemic on March 11, 2020, after it spread to over 118 countries.

Key Facts

First human cases of 2019-nCoV were reported in Wuhan, China, in December 2019
The virus was identified as SARS-CoV-2 by January 2020
WHO declared a global pandemic on March 11, 2020
As of April 2020, the global case fatality rate was estimated at 2-3%
SARS-CoV-2 spreads primarily through respiratory droplets and aerosols

Overview

2019-nCoV acute respiratory disease, later officially named COVID-19, emerged as a novel coronavirus-driven illness in late 2019. It originated in Wuhan, China, and rapidly evolved into a global health crisis due to its high transmissibility and unknown clinical profile.

The disease primarily affects the respiratory system, causing symptoms ranging from mild fever and cough to severe pneumonia and acute respiratory distress syndrome (ARDS). By March 2020, it had spread to over 118 countries, prompting unprecedented public health responses worldwide.

Initial outbreak: The first 41 confirmed cases were linked to the Huanan Seafood Wholesale Market in Wuhan, suggesting zoonotic transmission, with human-to-human spread confirmed by January 2020.
Incubation period: Symptoms typically appear 2–14 days after exposure, with a median incubation of 5 days, according to CDC and WHO analyses of early case clusters.
Common symptoms: Fever occurs in 88% of patients, dry cough in 68%, fatigue in 38%, and shortness of breath in 19%, based on a study of 1,099 patients published in NEJM.
Severe outcomes: Approximately 15–20% of cases progress to severe disease requiring hospitalization, with higher risks among those over 65 years old or with comorbidities like diabetes or heart disease.
Global detection: The U.S. reported its first case on January 20, 2020, in Washington State, traced to a traveler returning from Wuhan, marking the start of domestic transmission monitoring.

How It Works

The disease mechanism of 2019-nCoV involves viral entry into human cells via the ACE2 receptor, primarily in the respiratory tract. This triggers an immune response that, in severe cases, leads to systemic inflammation and organ damage.

Viral entry: SARS-CoV-2 binds to ACE2 receptors on respiratory epithelial cells using its spike protein, enabling viral RNA to enter host cells and initiate replication.
Replication: The virus replicates rapidly in the upper and lower respiratory tract, with peak viral shedding occurring 1–2 days before symptom onset, enhancing pre-symptomatic transmission.
Immune response: The body’s immune system releases cytokines, but in some patients, a cytokine storm occurs, causing widespread inflammation and lung damage.
Transmission: The virus spreads mainly through respiratory droplets within 6 feet, though aerosol transmission in enclosed spaces has been documented, especially in superspreader events.
Survival on surfaces: SARS-CoV-2 remains viable on plastic and stainless steel for up to 72 hours, though transmission via fomites is considered less common than airborne spread.
Asymptomatic spread: Studies estimate that 40–45% of transmissions occur from individuals who are pre-symptomatic or asymptomatic, complicating containment efforts.

Comparison at a Glance

Comparing 2019-nCoV to other respiratory viruses highlights differences in transmission, severity, and global impact.

Virus	Case Fatality Rate	R0 (Basic Reproduction Number)	Primary Transmission Route	Vaccine Availability
SARS-CoV-2 (2019-nCoV)	2–3%	2.5–3.5	Respiratory droplets, aerosols	Yes (by late 2020)
Influenza (H1N1)	0.02–0.05%	1.2–1.6	Droplets, contact	Yes (annual)
SARS-CoV-1 (2003)	9.6%	2–3	Droplets	No (outbreak contained)
MERS-CoV	34.4%	0.5–0.9	Camel contact, droplets	No
Rhinovirus (Common Cold)	Negligible	2–3	Droplets, fomites	No

The table shows that while SARS-CoV-2 is less fatal than SARS or MERS, its higher R0 and asymptomatic spread allowed it to become pandemic. Unlike influenza, no pre-existing immunity existed in the population, accelerating global spread.

Why It Matters

Understanding 2019-nCoV acute respiratory disease is crucial for public health planning, medical response, and future pandemic preparedness. Its emergence reshaped global health policies, travel, and economic systems.

Healthcare strain: Hospitals in Italy, Spain, and New York faced overcapacity by March 2020, with ICU beds and ventilators in critical shortage during peak waves.
Economic impact: The pandemic triggered a global recession, with the IMF estimating a 3.1% contraction in global GDP in 2020, the worst since the Great Depression.
Vaccine development: Multiple vaccines were developed in under 11 months, a historic achievement, with Pfizer-BioNTech and Moderna receiving EUA by December 2020.
Long-term effects: Up to 10% of patients experience prolonged symptoms, known as long COVID, including fatigue, brain fog, and respiratory issues lasting months.
Global cooperation: The WHO coordinated global surveillance and data sharing, though geopolitical tensions delayed early containment efforts and vaccine equity.
Public behavior: Mask mandates, social distancing, and remote work became widespread, altering daily life and accelerating digital transformation in education and business.

The emergence of 2019-nCoV underscored the vulnerability of interconnected societies to novel pathogens. It emphasized the need for robust surveillance, rapid diagnostics, and equitable vaccine distribution to prevent future pandemics.